

Invited Review

Recent studies on the biological action of parathyroid hormone (PTH)-related peptide (PTHrP) and PTH/PTHrP receptor in cartilage and bone

N. Amizuka¹, J.E. Henderson², J.H. White³, A.C. Karaplis², D. Goltzman⁴, T. Sasaki¹ and H. Ozawa¹

¹Department of Oral Anatomy, Niigata University Faculty of Dentistry, Niigata, Japan,

²Endocrine Division, S.M.M.B.D.-Jewish General Hospital, Lady Davis Institute for Medical Research, Montreal, Canada,

³Department of Physiology and Medicine, McGill University, Montreal, Canada and

⁴Department of Medicine, McGill University, Calcium Research Laboratory, Royal Victoria, Hospital, Montreal, Canada

Summary. Mice with a targeted deletion of parathyroid hormone (PTH)-related peptide (PTHrP) develop a form of dyschondroplasia resulting from diminished proliferation and premature maturation of chondrocytes. Abnormal, heterogeneous populations of chondrocytes at different stages of differentiation were seen in the hypertrophic zone of the mutant growth plate. Although the homozygous null animals die within several hours of birth, mice heterozygous for PTHrP gene deletion reach adulthood, at which time they show evidence of osteopenia. Therefore, PTHrP appears to modulate cell proliferation and differentiation in both the pre and post natal period. PTH/PTHrP receptor expression in the mouse is controlled by two promoters. We recently found that, while the downstream promoter controls PTH/PTHrP receptor gene expression in bone and cartilage, it is differentially regulated in the two tissues. $1\alpha,25\text{-dihydroxyvitamin D}_3$ downregulated the activity of the downstream promoter in osteoblasts, but not in chondrocytes, both *in vivo* and *in vitro*. Most of the biological activity of PTHrP is thought to be mediated by binding of its amino terminus to the PTH/PTHrP receptor. However, recent evidence suggests that amino acids 87-107, outside of the amino terminal binding domain, act as a nucleolar targeting signal. Chondrocytic cell line, CFK2, transfected with wild-type PTHrP cDNA showed PTHrP in the nucleoli as well as in the secretory pathway. Therefore, PTHrP appears to act as a bifunctional modulator of both chondrocyte proliferation and differentiation, through signal transduction linked to the PTH/PTHrP receptor and by its direct action in the nucleolus.

Key words: PTHrP, PTH/PTHrP receptor, Chondrocyte, Nucleolar targeting signal, $1\alpha, 25\text{-dihydroxyvitamin D}_3$.

Introduction

Parathyroid hormone (PTH)-related peptide (PTHrP) was first identified as a tumor derived factor that caused hypercalcemia in patients with a variety of malignancies (Burtis et al., 1987; Strewler et al., 1987; Suva et al., 1987). The high homology within the extreme amino termini of PTH and PTHrP permits them to bind to the common receptor, PTH/PTHrP receptor (Jüppner et al., 1991) on target cells in kidney and bone. Consequently, systemic PTHrP, released by the tumor, mimics the biological activity of PTH (Horiuchi et al., 1987; Kemp et al., 1987; Rabbani et al., 1988; Thompson et al., 1988). However, unlike PTH, which is the major regulator of calcium homeostasis, PTHrP does not circulate in significant quantities under normal circumstances. Rather, in view of the widespread expression of PTHrP and its receptor in a number of fetal and adult tissues (Ureña et al., 1993). It is thought to act as a local regulator of cell growth and differentiation (Merendino et al., 1986; Ikeda et al., 1988; Thiede and Rodan, 1988; Dmcker et al., 1989; Thiede et al., 1990; Moseley et al., 1991; Kaiser et al., 1992, 1994; Deftos et al., 1993). PTHrP is expressed during embryogenesis in mural trophoblast cells, in extra-decidual uterine stroma, in placenta, in the epithelial cells of the dental lamina including ameloblasts, in hair follicles, in keratinocytes, in nasal epithelial cell and in the membranous labyrinth, in epithelial cells in the lung, and in cartilage and bone (Senior et al., 1990; Lee et al., 1994).

Our studies using a mouse with targeted deletion of the PTHrP gene, developed by Karaplis et al. in 1994, demonstrated that PTHrP plays a key role in chondro-osteogenesis (Karaplis et al., 1994). Mice homozygous

Offprint requests to: Dr. Norio Amizuka, D.D.S., D.D.Sc., Department of Oral Anatomy, Niigata University, Faculty of Dentistry, 5274, 2-Bancho, Gakkouchou-Dori, Niigata, 951-8514, Japan. Fax: +81-25-227-0804. e-mail: amizuka@dent.niigata-u.ac.jp

for a null mutation of the PTHrP gene die within hours of birth with skeletal abnormalities consistent with osteochondrodysplasia. Our analysis of these homozygous null mutants indicates that the abnormalities are related to perturbations in both proliferation and differentiation of chondrocytes (Amizuka et al., 1994). Adult mice heterozygous for targeted ablation of the PTHrP gene demonstrated reduced expression of PTHrP, but normal levels of PTH. This PTHrP deficient mouse developed a form of osteopenia showing disturbed formation of bony trabecules (Amizuka et al., 1996a), suggesting that PTH could not sub-serve the function of PTHrP in these animals.

The expression of the mouse PTH/PTHrP receptor is regulated by at least two promoters (McCuaing et al., 1994, 1995) which give rise to two transcripts that differ in their 5' untranslated regions but not in their coding sequences. Transcripts from the upstream promoter, P1, contain sequences derived from two 5' untranslated region exons U1 and U2, and are highly and selectively expressed in kidney (Amizuka et al., 1997). P1 functions in all renal cell types expressing the PTH/PTHrP receptor, including tubular epithelial cells, peritubular endothelial cells, glomerular podocytes and vascular smooth muscle (Amizuka et al., 1997). The downstream promoter, P2, gives rise to transcripts that contain 5' untranslated sequences derived from exon U3. P2 function is restricted to tubular epithelial cells in kidney. However, it is active in a wide variety of other tissues, including bone and cartilage, and accounts for the broad expression pattern of the PTH/PTHrP receptor. Recently, we performed *in situ* hybridization studies with probes specific for transcripts expressed from P1 or P2, and found that P2 is the predominant PTH/PTHrP receptor promoter in bone and cartilage (Amizuka et al., 1999). We also found that PTH/PTHrP receptor expression is differentially modulated in bone and cartilage by $1\alpha,25\text{-dihydroxyvitamin D}_3$ [$1\alpha,25(\text{OH})_2\text{D}_3$]. $1\alpha,25(\text{OH})_2\text{D}_3$ inhibited expression of the PTH/PTHrP receptor in osteoblasts, but not chondrocytes, both *in vivo* and *in vitro* through downregulation of P2 activity (Amizuka et al., 1997). These studies add another facet to the complex interplay of the calcium regulatory functions of $1\alpha,25(\text{OH})_2\text{D}_3$, PTH and PTHrP.

In addition to its activity mediated through binding of the amino terminus to the PTH/PTHrP receptor, we and others have reported bioactivity mediated through mid-region amino acids 87-107, which represent a nuclear/nucleolar targeting signal (NTS). Although the presence of the PTHrP leader sequence preferentially targets the protein to the secretory pathway, in the absence of the leader sequence, PTHrP is preferentially targeted to the nucleolus in transfected chondrocytic cells (Henderson et al., 1995). In the absence of the NTS, PTHrP localized exclusively to the cytoplasmic compartment.

Thus, this paper will review recent studies, performed by ourselves and others, on PTHrP and the

amino terminal PTH/PTHrP receptor. These include the histological abnormalities of the PTHrP deficient mouse, the alternative suppression of PTH/PTHrP receptor transcripts by $1\alpha,25(\text{OH})_2\text{D}_3$, and the nuclear/nucleolar targeting of PTHrP in chondrocytic cells.

Skeletal alterations of the fetal mice homozygous for PTHrP gene deletion

E18-19 day fetal mice homozygous null for the PTHrP gene had shortened limbs, protruding tongues, hypoplastic mandibles and square-shaped calvariae (Karaplis et al., 1994) (Fig. 1A). These dysmorphic characteristics resulted from reduced proliferation and premature differentiation of chondrocytes during endochondral bone formation (Fig. 1B,C). The epiphyseal growth plate of wild-type mice is composed of distinct regions referred to as the resting zone, the proliferative zone and the hypertrophic zone. The epiphyses of PTHrP deficient mice had fewer resting and proliferative chondrocytes, although the number of hypertrophic cells did not seem to be altered (Amizuka et al., 1994). In addition, a heterogeneous cell population was observed in the hypertrophic zone of mutant mice, with clusters of non-hypertrophic chondrocytes persisting among the hypertrophic cells (Fig. 2). This was in contrast to the uniform region of hypertrophic cells seen in wild-type mice. The persistence of non-hypertrophic cells up to the metaphyseal side of the epiphyseal plate distorted the longitudinal columns of hypertrophic chondrocytes, resulting in less-developed longitudinal septae of calcified cartilage matrix (Fig. 3). These non-hypertrophic chondrocytes were characterized by expression of the PTH/PTHrP receptor and continued cell proliferation as well as active protein synthesis, evidenced by incorporation of [^3H] thymidine and [^3H] proline, respectively (data not shown). These cells, therefore, displayed the same properties as resting and proliferative chondrocytes. These studies demonstrated that PTHrP modulates chondrocyte proliferation and differentiation during the fetal period.

Skeletal alterations in adult mice heterozygous for PTHrP gene deletion

Mice heterozygous for targeted disruption of the PTHrP gene reveal no obvious abnormalities at birth. However, a haploinsufficient phenotype was apparent by 3 months of age, which was characterized by short, blunt snouts and generalized osteopenia (Amizuka et al., 1996a) (Fig. 4). PTHrP mRNA was significantly reduced in the heterozygous mice compared with their wild-type littermates. However, plasma PTH and calcium concentrations were normal. Scanning electron microscopic analysis of the metaphysis of 3-month old wild-type mice, revealed uniform bone spicules, which were aligned parallel to the longitudinal axis (Fig. 4B,C). In contrast, the bony spicules in the metaphysis



The biological action of PTHrP and its receptor in skeletal tissue

of heterozygous mice were fewer in number and were not distributed longitudinally. The growth plate of the heterozygotes demonstrated disorganized column of proliferating cells with subsequent distortion of the

longitudinal cartilage partitions (Fig. 4D,E). This local failure to form uniform intercolumnar partitions of cartilage matrix most probably accounted for the abnormal distribution of mixed spicules. The



Fig. 1. **A.** Binocular microscopic observation of an 18.5-day old wild-type fetus (left) and a littermate homozygous (right) for PTHrP gene deletion (quoted from Amizuka et al., 1994; Karaplis et al., 1994). The homozygote shows characteristic abnormalities including a protruding tongue, square-shaped calvaria and short limbs, compared with those of normal litter mates. Bar; 0.5 μ m. **B, C.** Low power images of proximal tibiae of PTHrP-normal (B) and PTHrP-deleted (C) fetuses at 18.5 days of gestation. The epiphyseal cartilage of PTHrP-deficient mice (C) is less-developed due to markedly reduced resting and proliferative zones, compared with those of the wild-type littermates (B). Bar: 50 μ m.



proliferative capacity of growth plate chondrocytes in the heterozygous mutants was also significantly reduced (data not shown). Thus, PTHrP appears to modulate normal chondrocyte proliferation and differentiation in adult, as well as fetal mice.

Localization of PTHrP and PTH/PTHrP receptor in

cartilage and bone

As PTHrP is believed to act primarily at the local level, it is important to identify cells that express the PTH/PTHrP receptor, in relation to PTHrP expressing cells, in the cartilage and bone microenvironment.




Fig. 2A, B. Light microscopic image of the hypertrophic zone of the wild-type (A) and littermates homozygous (B) for PTHrP-deficiency (quoted from Amizuka et al., 1994). The hypertrophic zone of wild-type littermates is composed of hypertrophic cells (A). However, the homozygote shows non-hypertrophic chondrocytes (arrowheads) interspersed among normal hypertrophic cells in the hypertrophic zone (B). Bar: 10 μ m
C. Electron microscopic image of hypertrophic chondrocytes (HC) and non-hypertrophic chondrocytes (NHC) in the hypertrophic zone of the PTHrP-deficient animal. P: proliferative zone; H: hypertrophic zone. Bar: 5 μ m

[¹²⁵I]-PTH radioautography previously performed by Goltzman and his colleagues identified mature osteoblasts and preosteoblasts as PTH target cells

(Rouleau et al., 1986, 1988, 1990). The preosteoblastic cell type, referred to as a "PT-cell", displayed extended cytoplasmic processes, and formed cell-to-cell contacts




Fig. 3. A, B. *In situ* hybridization for expression of osteonectin in the tibiae of the wild-type (Normal, A) and the homozygote for PTHrP-deletion (Homo, B). The wild-type animal has extended longitudinal trabeculae where osteoblasts express the osteonectin gene as indicated in brown (A), whereas osteoblasts in the cortical bone but not trabecular bones show the expression of osteonectin in the homozygote (B). Bar: 50 μ m. **C, D.** Osteocalcin immunoreactivity on the trabecular bones of the wild-type (C) and homozygote (D). Osteocalcin immunoreactivity seen in black is located in the periphery of the longitudinal cartilage cores (cc) (C), while the homozygote shows irregularly-shaped cartilage cones (cc), resulting in the disorganized accumulation of osteocalcin (D). Bar: 20 μ m

The biological action of PTHrP and its receptor in skeletal tissue




Fig. 4. **A.** Left and right show a 3-month old wild-type (Normal) and a littermate heterozygous for PTHrP gene deletion (Heterozygous), respectively. Note the less-protruded snout of the heterozygote (arrow). Bar: 0.3 μ m. **B, C.** Scanning electron microscopy displayed the epiphyseal and metaphyseal trabecular bones of femura of the wild-type and heterozygote. The heterozygous animal (C) reveals irregularly distributed trabeculae compared to the wild-type littermate (B). Bar: 0.5 μ m. **D, E.** The histological sections of the epiphyseal growth plate (GP) of the wild-type mouse and a littermate heterozygous for PTHrP gene deletion. In the wild-type, longitudinal cartilaginous columns are well formed, while the heterozygote displays poorly-developed columns (quoted from Amizuka et al., 1996a). Bar: 50 μ m

The biological action of PTHrP and its receptor in skeletal tissue

with neighbouring osteoblasts. Our later studies, using *in situ* hybridization and immunocytochemistry verified the presence of PTH/PTHrP receptor mRNA and protein in osteoblasts and preosteoblasts (Amizuka et al., 1996a-c; Irie and Ozawa, 1996) (Fig. 5). These observations have also been corroborated using Northern blot and chemical analyses of osteoblastic cells in culture. These later studies revealed an upregulation of PTH/PTHrP receptor during osteoblast differentiation (Abou-Samura et al.,

1992; Suda et al., 1996). In the developing murine growth plate, the PTH/PTHrP receptor is broadly distributed throughout the resting and proliferative zones, up to the proximal region of the hypertrophic zone (Lee et al., 1994; Amizuka et al., 1996a-c, Irie and Ozawa, 1996). This localization of the PTH/PTHrP receptor almost overlapped with that of the proliferating cells identified by [³H] thymidine radioautography and immunocytochemical localization of the proliferating




Fig. 5. A, B. The localization of the gene and protein of PTHrP in bone tissue. In situ hybridization (A) and immunocytochemistry (B) for PTHrP in bone tissue (quoted from Amizuka et al., 1996a). The PTHrP gene is expressed in osteoblasts (OB) as shown by the brown color (A). Weak immunoreactivity for PTHrP (brown) is seen in osteoblasts located on trabecular bones (TB) (B). Bar: 20 μ m. **C.** Double-labeled in situ hybridization for PTHrP and the PTH/PTHrP receptor in bone tissue. PTHrP and the PTH/PTHrP receptor are represented by the brown and by silver grains, respectively. Osteoblasts show co-localization of genes encoding the ligand and the receptor, therefore suggesting a paracrine/autocrine mode of action of the ligand. The receptor gene is also broadly expressed in preosteoblastic cells. Note silver grains, but not red brown color in the preosteoblastic cells (arrows). Bar: 20 μ m

cell nuclear antigen (Amizuka et al., 1996b). It seems likely, therefore, that the inhibition of chondrocyte proliferation observed in the PTHrP deficient mice was primarily due to a reduction in the interaction of PTHrP with the PTH/PTHrP receptor on proliferating chondrocytes. In the murine growth plate, localization of PTHrP mRNA and protein was restricted to resting chondrocytes, to chondrocytes at the junction between proliferative and hypertrophic zones (Amizuka et al., 1994, Weir et al., 1996), and differentiated osteoblasts (Amizuka et al., 1996a, Suda et al., 1996, Lomri et al., 1997). Northern analysis has also revealed expression of the PTHrP gene in epiphyseal cartilage (Tsukazaki et al., 1995). In addition, cultured osteoblastic cell lines demonstrated PTHrP expression and binding of the protein to their cell surface (Enomoto et al., 1993). Taken together, these observations indicate that PTHrP is synthesized in cartilage and in bone where it acts in a paracrine/autocrine fashion.

In contrast to osteoblasts and chondrocytes, many studies have reported that osteoclasts do not possess the PTH/PTHrP receptor, however, the expression of the PTH/PTHrP receptor gene in osteoclasts has recently been discussed (Athanasou and Sabokbar, 1999; Langub et al., 1999). Langub et al. have demonstrated that the receptor gene could be detected in both normal human and patients suffering from secondary hyperparathyroidism. Yet, it was observed the most osteoclasts from patients were immunopositive for the receptor protein, while no staining was detected in osteoclasts from normal subjects. They, therefore, predicted that PTH/PTHrP receptor mRNA would be detectable in osteoclasts in both normal and hyperparathyroid patients, but translation to the receptor protein is achieved only in patients with hyperparathyroidism. It is of interest that PTH/PTHrP receptor mRNA would be subjected to translation in the osteoclasts under pathological circumstances, suggesting the possibility of the direct effect of PTH and PTHrP to osteoclasts.

Regulation of PTHrP expression by indian hedgehog and TGF β

A mouse with targeted deletion of the PTH/PTHrP receptor has also been generated in Boston (Lanske et al., 1996). The receptor deficient mouse showed almost the same abnormalities in epiphyseal cartilage and endochondral bone as those seen in PTHrP deficient mice. However, the PTH/PTHrP receptor-null mice died in mid-gestation. This was attributed to the fact that the





activity of maternal PTHrP was blocked in these mice. In contrast to the PTHrP deficient animal, a mouse in which PTHrP overexpression was driven by collagen II promoter, developed at Yale University, exhibited enhanced chondrocyte proliferation, delayed chondrocyte maturation, and inhibition of endochondral bone formation (Weir et al., 1996). This transgenic model, therefore, demonstrated the abnormalities in endochondral bone formation which were reverse of those seen in the PTHrP and PTH/PTHrP receptor deficient mice. To further examine the pathways linked to PTHrP signalling during bone development, investigators in Boston examined the regulation of PTHrP by indian hedgehog (IHH), one of the family of hedgehog morphogens known to be involved in bone formation. Those studies demonstrated IHH expression in developing cartilage was restricted to a sub-set of cells at the junction between the proliferative and hypertrophic zones (Vortkamp et al., 1996). Vortkamp et al. also employed a model of IHH-misexpression in chick limb cartilage, to demonstrate that the protein inhibited chondrocyte differentiation and stimulated expression of PTHrP mRNA. It was hypothesized that PTHrP was downstream of IHH in a negative feedback loop that modulates the rate of chondrocyte differentiation.

Recently, Serra et al. have demonstrated that transforming growth factor β (TGF β) and PTHrP act in a common signalling cascade to regulate endochondral bone formation (Serra et al., 1999). Using an organ explant model of embryonic murine metatarsal bone rudiments, they demonstrated that TGF β inhibited chondrocyte proliferation, hypertrophic differentiation, and matrix mineralization. Treatment with TGF β 1 also promoted the expression of PTHrP, resulting in the inhibition of hypertrophic differentiation and matrix mineralization but did not affect cell proliferation. However, terminal differentiation of chondrocytes was not inhibited by TGF β when the in metatarsal rudiments were removed from PTHrP-null mice, suggesting that TGF β acts upstream of PTHrP to inhibit chondrocyte differentiation.

Mutations in the PTH/PTHrP receptor gene in Jansen-type metaphyseal chondrodysplasia and blomstrand chondrodysplasia

In 1995, a point mutation in the gene encoding the PTH/PTHrP receptor was discovered in a patient with Jansen-type metaphyseal chondrodysplasia, which is a

Fig. 6. A, B. *In situ* hybridization to detect gene expression of the PTH/PTHrP receptor coding region transcripts in the control and $1\alpha,25(\text{OH})_2\text{D}_3$ -treated mouse tibiae (quoted from Amizuka et al., 1999). **A:** In the control tibiae (D-), hybridization signals (dark brown) corresponding to expression of the PTH/PTHrP receptor coding region were detected in metaphyseal osteoblasts and in chondrocytes of the growth plate (GP). **B:** The $1\alpha,25(\text{OH})_2\text{D}_3$ -treated tibia (D+) showed only a weak hybridization signal (faint brown color) in osteoblasts. Chondrocytes maintained an intense signal indicating strong PTHR coding region expression in the growth plate (GP). **C, D.** *In situ* hybridization detecting gene expression of P2 promoter-specific transcripts in control and $1\alpha,25(\text{OH})_2\text{D}_3$ -treated mouse tibiae. **C:** Control tibiae showed strong gene expression of P2 specific transcripts (brown color) in metaphyseal osteoblasts and in chondrocytes of the growth plate. **D:** $1\alpha,25(\text{OH})_2\text{D}_3$ -treated tibiae showed reduced expression of P2-specific transcripts in osteoblasts. Strong gene expression was still observed in the growth plate chondrocytes. B: bone. Bar: 50 μm .



heritable form of dwarfism associated with hypercalcemia (Schipani et al., 1995). The mutation in the first intracellular domain results in the substitution of a conserved histidine residue, at position 223, to an arginine. Another mutation, which substitute a threonine with a proline at position 410 in the sixth membrane-spanning domain, has also been identified in Jansen patients (Schipani et al., 1996). These mutations result in ligand-independent accumulation of cAMP suggesting that residues 223 and 410 play a critical role in PTH/PTHrP receptor signal transduction. In contrast, Jobert et al. recently reported an inactivating mutation in the gene encoding the PTH/PTHrP receptor. The G/A substitution at nucleotide 1176, inherited from the mother, cause an 11 amino acid deletion in the first part of the fifth transmembrane domain and results in Blomstrand's chondrodysplasia, which is characterized by premature endochondral bone formation (Jobert et al., 1998). The mutant receptor can not bind PTH or PTHrP, and failed to stimulate production of cAMP or inositol phosphate. More recently, Karaplis et al. identified a single nucleotide exchange, which results in a proline to leucine substitution at position 132 in the amino terminal extracellular domain, in an infant with Blomstrand chondrodysplasia (Karaplis et al., 1999). This mutant

receptor also failed to bind PTH or PTHrP, suggesting that proline 132 is critical for the receptor's intrinsic binding activity.

Regulation of the PTH/PTHrP receptor transcription by $1\alpha,25(\text{OH})_2\text{D}_3$

Calcium homeostasis is largely controlled by PTH through signalling pathways linked to the PTH/PTHrP receptor and by $1\alpha,25(\text{OH})_2\text{D}_3$. PTH, which is secreted by the parathyroid gland in response to a reduction in extracellular fluid calcium, mobilizes calcium from bone and stimulates its reabsorption in the kidney (Muff et al., 1992; Backsai and Friedman, 1995). $1\alpha,25(\text{OH})_2\text{D}_3$ also stimulates bone resorption and calcium release from bone, and in addition enhances calcium absorption in the intestine (Wasserman and Fullmer et al., 1983; Deluca, 1985; Hock et al., 1986). The interplay between PTH and $1\alpha,25(\text{OH})_2\text{D}_3$ is complex. $1\alpha,25(\text{OH})_2\text{D}_3$ has been shown to downregulate expression of PTH in the parathyroid glands (Delmez et al., 1989; Naveh-Many and Silver, 1990) whereas PTH acts to promote formation of active $1\alpha,25(\text{OH})_2\text{D}_3$ by stimulating the expression of the 1α -hydroxylase enzyme in the kidney that converts the inactive 25-hydroxy precursor to the




Fig. 7. A, B. Immunohistochemical analysis of PTH/PTHrP receptor protein in the control (A) and $1\alpha,25(\text{OH})_2\text{D}_3$ -treated (B) bone (quoted from Amizuka et al., 1999). **A.** PTH/PTHrP receptor-immunoreactivity (brown color) is observed in osteoblasts (ob) and chondrocytes in the growth plate (GP) of control animals. **B.** PTH/PTHrP receptor immunoreactivity in chondrocytes (arrowheads) from $1\alpha,25(\text{OH})_2\text{D}_3$ -treated animals was not altered significantly, whereas immunoreactivity in osteoblasts (ob) was noticeably decreased after $1\alpha,25(\text{OH})_2\text{D}_3$ -treatment. Bar: 20 μm .

active $1\alpha, 25$ -dihydroxy form of D_3 (Goltzman and Hendy, 1995).

We have examined the effect of $1\alpha, 25(OH)_2D_3$ on PTH/PTHrP receptor gene expression in bone and cartilage. Expression of the PTH/PTHrP receptor is controlled by at least two promoters, P1 and P2 (McCuaing et al., 1994, 1995). The downstream promoter, P2 is ubiquitously expressed, whereas expression of the upstream promoter, P1 is largely restricted to kidney (Amizuka et al., 1997). *In situ* hybridization with an antisense probe recognizing P1-specific transcript, revealed only weak signals in both osteoblasts and chondrocytes. Conversely, the downstream promoter P2 is highly expressed both in growth plate chondrocytes and in osteoblasts lining the bony trabeculae (Amizuka et al., 1999). The distribution of PTH/PTHrP receptor coding sequences detected in mouse tibiae was essentially identical to that of P2-

specific sequences. $1\alpha, 25(OH)_2D_3$ -treatment *in vivo* markedly decreased the expression of the PTH/PTHrP receptor coding region in both preosteoblasts and osteoblasts (Figs. 6A,B, 7). In contrast, PTH/PTHrP receptor expression in chondrocytes remained high. A similar pattern of differential regulation in osteoblasts and chondrocytes was observed when tibiae from $1\alpha, 25(OH)_2D_3$ -treated animals were analyzed with a probe complementary to P2-specific transcripts (Amizuka et al., 1999) (Fig. 6C,D). The inhibitory effects on $1\alpha, 25(OH)_2D_3$ were also observed *in vitro* in the osteoblastic cell line, MC3T3-E1, but not in CFK 2 chondrocytic cells. Gene transfer experiments suggested that this inhibition was due to cell-specific repression of P2 function by $1\alpha, 25(OH)_2D_3$ in osteoblasts but not in chondrocytes (data not shown). The regulation of PTH/PTHrP receptor gene expression by $1\alpha, 25(OH)_2D_3$ in osteoblasts but not in chondrocytes indicates that the

Nucleolar translocation of PTHrP




Fig. 8. Immunocytochemical localization of PTHrP in stably transfected CFK 2 cells (quoted from Henderson et al., 1995). Populations of CFK 2 chondrocytes stably transfected with the various constructs were prepared. **A.** Cytoplasmic and nucleolar immunoreaction for PTHrP is seen in CFK 2 cells transfected with wild-type PTHrP cDNA. **B.** CFK 2 transfected with PTHrP cDNA deleted pre-pro region shows only nucleolar localization of PTHrP protein. **C.** CFK 2 transfected with PTHrP cDNA deleted nucleolar targeting signal shows cytoplasmic PTHrP protein.

interplay between the two signalling pathways is specific to their overlapping roles in controlling calcium mobilization in bone, and not to their complementary effects on proliferation and maturation of chondrocytes.

Nuclear targeting of PTHrP

It is currently believed that the majority of the biological activity of PTHrP is mediated through the interaction of its amino terminus with the common PTH/PTHrP cell surface receptor. However, recent work has established an alternative, intracellular mechanism of action for PTHrP. Thus, amino acids 87-107 of PTHrP represent a bipartite nuclear targeting signal that is homologous to nucleolar targeting signal (NTS) found in certain retroviral regulatory proteins such as Rex, Rev and Tat. Henderson et al. have demonstrated that the PTHrP NTS directed passage of both PTHrP and heterologous, cytoplasmic proteins to the nuclear compartment of the transfected cells (Henderson et al., 1995) (Fig. 8). PTHrP has been localized to the nucleus and nucleoli of a sub-set of cells *in vitro* and *in vivo*. Immunoelectron microscopy localized PTHrP to the coarse fibrillar component of the nucleolus, which is where newly transcribed ribosomal RNA is found. In addition, the presence of nucleolar PTHrP was shown to protect serum-deprived CFK 2 chondrocytic cells from apoptotic cell death. The effects of constitutive expression of PTHrP on the proliferation and differentiation of CFK 2 chondrocytes was also examined (Henderson et al., 1996). Populations of cells expressing both secretory and non-secretory forms of PTHrP demonstrated almost complete inhibition of mRNA expression for matrix proteins. Administration of exogenous PTHrP could not fully mimic these effects suggesting that they were mediated through pathways independent of those linked to signal transduction downstream of the PTH/PTHrP receptor.

Corroborative evidence for the anti-apoptotic role of PTHrP comes from our *in vivo* studies of PTHrP-deficient mice (Amizuka et al., 1996b). In the lower region of the hypertrophic zone of the epiphyseal cartilage of the homozygous mice, many apoptotic chondrocytes were identified *in situ* by endo-labeling of fragmented DNA with TUNEL staining. In contrast, age-matched wild type littermates demonstrated few such apoptotic chondrocytes suggesting that apoptosis was accelerated in the growth plates of PTHrP-deficient mice.

With respect to the potential function of PTHrP in the nucleolus, Aarts et al. recently demonstrated that PTHrP associated with endogenous and homopolymeric RNA through its NTS (Aarts et al., 1999). Site-directed mutagenesis revealed that the association was dependent on preservation of a GXKKXXX motif embedded in the PTHrP NTS, which is conserved amongst double stranded RNA binding proteins. Taken together, with the location of PTHrP in the coarse fibrillar component of the nucleolus, it is hypothesized that its RNA-binding

activity predicts a role for PTHrP in the regulation in the nucleoli of a sub-set of randomly cycling cells.

Acknowledgments. Norio Amizuka is a recipient of Kato Bioscience Foundation and a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan. Janet E. Henderson and John H. White are Chercheur-Boursier of the Fonds de la Recherche en Santé du Québec, and Andrew C. Karaplis is an MRC Scientist. These studies were supported in part by Medical Research Council of Canada grants to Janet E. Henderson, John H. White, Andrew C. Karaplis and David Goltzman, and from the National Cancer Institute of Canada to John H. White, Andrew C. Karaplis and David Goltzman.

References

- Aarts M.M., Levy D., He B., Stregger S., Chen T., Richard S. and Henderson J.E. (1999). Parathyroid hormone-related protein interacts with RNA. *J. Biol. Chem.* 274, 4832-4838.
- Abou-Samra A.-B., Jüppner H., Force T., Freeman M.W., Kong X.F., Schipani E., Ureña P., Richards J., Bonventre J.V., Potts J.T., Kronenberg H.M. and Segre G.V. (1992). Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol triphosphates and increases intracellular free calcium. *Proc. Natl. Acad. Sci. USA* 89, 2732-2736.
- Amizuka N., Warshawsky H., Henderson J.E., Goltzman D. and Karaplis A.C. (1994). Parathyroid hormone-related peptide (PTHrP)-depleted mice show abnormal epiphyseal cartilage and altered endochondral bone formation. *J. Cell Biol.* 126, 1611-1623.
- Amizuka N., Karaplis A.C., Henderson J.E., Warshawsky H., Lipman M.L., Matsuki Y., Ejiri S., Tanaka M., Izumi N., Ozawa H. and Goltzman D. (1996a). Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal post-natal bone development. *Dev. Biol.* 175, 166-176.
- Amizuka N., Karaplis A.C., Henderson J.E., Hoshi K., Warshawsky H., Ozawa H. and Goltzman D. (1996b). Programmed cell death of chondrocytes and aberrant chondrogenesis in mice homozygous for parathyroid hormone-related peptide (PTHrP) gene deletion. *Endocrinology* 137, 5055-5067.
- Amizuka N., Goltzman D. and Ozawa H. (1996c). The biologic action of parathyroid hormone-related peptide on bone cells. *Tissue Engineering* 2, 277-287.
- Amizuka N., Lee H.S., Kwan M.Y., Arazani A., Warshawsky H., Ozawa H., White J.H. and Goltzman D. (1997). Cell-specific expression of the parathyroid hormone (PTH)/PTH-related peptide receptor gene in rat kidney from kidney-specific and ubiquitous promoters. *Endocrinology* 138, 469-481.
- Amizuka N., Kwan M., Goltzman D., Ozawa H. and White J.H. (1999). Vitamin D3 differentially regulates parathyroid hormone/parathyroid hormone-related peptide receptor expression in bone and cartilage. *J. Clin. Invest.* 103, 373-381.
- Athanasou N.A. and Sabokbar A. (1999). Human osteoclast ontogeny and pathological bone resorption. *Histol. Histopathol.* 14, 635-647.
- Bacskai B.J. and Friedman P.A. (1995). Activation of latent calcium channels in renal epithelial cells by parathyroid hormone. *Nature* 347, 388-391.
- Burtis W.J., Wu T., Bunch C., Wysolmerski J.J., Isogna K.L., Weir E.C.,

The biological action of PTHrP and its receptor in skeletal tissue

- Broadus A.E. and Stewart A.F. (1987). Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy. *J. Biol. Chem.* 161, 7151-7156.
- Deftos L.J., Burton D.W. and Brant D.W. (1993). Parathyroid hormone-like protein is a secretory product of atrial myocytes. *J. Clin. Invest.* 92, 727-735.
- Delmez J.A., Tindira C., Grooms P., Dusso A., Windus D. and Slatopolsky E. (1989). Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium. *J. Clin. Invest.* 83, 1349-1355.
- DeLuca H.F. (1985). Vitamin D-dependent calcium transport. *Society of General Physiologist Series.* 39, 159-176.
- Drucker D.J., Asa S.L., Henderson J. and Goltzman D. (1989). The parathyroid hormone-like peptide gene is expressed in the normal and neoplastic human endocrine pancreas. *Mol. Endocrinol.* 3, 1589-1595.
- Enomoto H., Yamashita S., Usa T., Namba H., Ohtsuru A., Villalid M.C., Tsukazaki T., Matsumoto T. and Iwasaki K. (1993). Autocrine/paracrine function of parathyroid hormone-related peptide in rat osteoblast-like cells. *Biochem. Biophys. Res. Commun.* 191, 1261-1269.
- Goltzman D. and Hendy G.N. (1995). Parathyroid hormone. In: *Principles and practice of endocrinology and metabolism.* 2nd ed. Becker K.L. (ed) J.B. Lippincott Co. Philadelphia, pp 455-467.
- Henderson J.E., Amizuka N., Warshawsky H., Biasotto D., Lanske B.M.K. Goltzman D. and Karaplis A.C. (1995). Nucleolar targeting of PTHrP enhances survival of chondrocytes under conditions that promote cell death by apoptosis. *Mol. Cell Biol.* 15, 4064-4075.
- Henderson J.E., He B., Goltzman D. and Karaplis A.C. (1996). Constitutive expression of parathyroid hormone-related peptide (PTHrP) stimulates growth and inhibits differentiation of CFK2 chondrocytes. *J. Cell. Physiol.* 169, 33-41.
- Hock J.M., Gunness-Hey M., Poser J., Olson H., Bell N.H. and Raize L.G. (1986). Stimulation of undermineralized matrix formation by 1,25-dihydroxyvitamin D3 in long bones of rats. *Calcif. Tissue Int.* 38, 79-86.
- Horiuchi N., Caulfield M.P., Fisher J.E., Goldman M.E., McKee G.R. Reagan J.E., Levy J.J., Nutt R.F., Rodan S.B., Clemens T.L. and Rosenblatt M. (1987). Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro. *Science* 238, 1566-1568.
- Ikeda K., Weir E.C., Mangin M., Dannies P.S., Kinder B. Deftos L.J., Brown E.M. and Broadus A.E. (1988). Expression of messenger ribonucleic acids encoding a parathyroid hormone-like peptide in normal human and animal tissues with abnormal expression in human parathyroid adenomas. *Mol. Endocrinol.* 2, 1230-1236.
- Irie K. and Ozawa H. (1996). Immunohistochemical localization of parathyroid hormone/parathyroid hormone-related peptide receptor in rat tibiae. *J. Bone Miner. Metab.* 14, 10-14.
- Jobert A.S., Zhang P., Couvineau A., Bonaventure J., Roume J., Le Merrer M. and Silve C. (1998). Absence of functional receptors for parathyroid hormone and parathyroid hormone-related peptide in Blomstrand chondrodysplasia. *J. Clin. Invest.* 102, 34-40.
- Jüppner H., Abou-Samra A.-B., Freeman M., Kong X.F., Schipani E., Richards J., Kolakowski Jr L.F., Hock J., Potts Jr J.T., Kronenberg H.M. and Segre G.V. (1991). A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. *Science* 254, 1024-1026.
- Kaiser S., Laneuville P., Bernier S.M., Rhim J.S., Kremer R. and Goltzman D. (1992). Enhanced growth of a human keratinocyte cell line induced by antisense RNA for parathyroid hormone-related peptide. *J. Biol. Chem.* 267, 13623-13628.
- Kaiser S.M., Sebag M., Rhim J.S., Kremer R. and Goltzman D. (1994). Antisense-mediated inhibition of parathyroid hormone-related peptide (PTHrP) production in a keratinocyte cell line impedes differentiation. *Mol. Endocrinol.* 8, 139-147.
- Karaplis A.C., Luz A., Glowacki J., Bronson R.T., Tybulewicz V.L.J., Kronenberg H.M. and Mulligan R.C. (1994). Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide (PTHrP) gene. *Genes Dev.* 8, 277-289.
- Karaplis A.C., He B., Nguyen M.T., Young I.D., Semeraro D., Ozawa H. and Amizuka N. (1999). Inactivating mutation in the human parathyroid hormone receptor type 1 gene in Blomstrand chondrodysplasia. *Endocrinology* 139, 4753-4755.
- Kemp B.E., Moseley J.M., Rodda C.P., Ebeling P.R., Wettenhall R.E.H., Stapleton D., Diefenbach-Jagger N., Ure F., Michlangeli V.P., Simmons H.A., Raisz L.G. and Martin T.J. (1987). Parathyroid hormone-related protein of malignancy: active synthetic fragments. *Science* 238, 1568-1570.
- Langub M.C., Faugere M.C., Qi O., Koszewski N.J. and Malluche H.H. (1999). Presence of mRNA for PTH/PTHrP receptors in human osteoclasts with evidence for translation to its protein pathologic but not normal condition. *J. Bone Miner. Res.* 14, S242.
- Lanske B., Karaplis A.C., Lee K., Luz A., Vortkamp A., Pirro A., Karperien M., Defize L.H.K., Ho C., Mulligan R.C., Abou-Samra A.B., Jüppner H., Segre G.V. and Kronenberg H.M. (1996). PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. *Science* 273, 663-666.
- Lee K., Deeds J.D., Chibs S., Un-no M., Bond A.T. and Segre G.V. (1994). Parathyroid hormone induces sequential c-fos expression in bone cells in vivo: In situ hybridization of its receptor and c-fos messenger ribonucleic acid. *Endocrinology* 134, 441-450.
- Lomri A., de Pollak C., Sebag M., Goltzman D., Kremer R. and Marie P.J. (1997). Expression of parathyroid hormone-related peptide (PTHrP) and PTH/PTHrP receptor in newborn human calvaria osteoblastic cells. *Eur. J. Endocrinol.* 136, 640-648.
- McCuaig K.A., Clarke J.C. and White J.H. (1994). Molecular cloning of the gene encoding the mouse parathyroid hormone/parathyroid hormone-related peptide receptor. *Proc. Natl. Acad. Sci. USA* 91, 5051-5055.
- McCuaig K.A., Lee H., Clarke J.C., Assar H., Horsford J. and White J.H. (1995). Parathyroid hormone/parathyroid hormone related peptide receptor gene transcripts are expressed from tissue-specific and ubiquitous promoters. *Nucleic Acids Res.* 23, 1948-1955.
- Merendino J.J., Isogna Jr K.L., Milstone L.M., Broadus A.E. and Stewart A.F. (1986). A parathyroid hormone-like protein from cultured human keratinocytes. *Science* 231, 388-390.
- Moseley J.M., Hayman J.A., Danks J.A., Alcorn D., Grill V., Southby J. and Horton M.A. (1991). Immunohistochemical detection of parathyroid hormone-related protein in human fetal epithelia. *J. Clin. Endocrinol. Metab.* 73, 478-484.
- Muff R., Fischer J.A., Biber J. and Murer H. (1992). Parathyroid hormone receptors in control of proximal tubule function. *Annu. Rev. Physiol.* 54, 67-79.
- Naveh-Many T. and Silver J. (1990). Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. *J. Clin. Invest.* 86, 1313-1319.

The biological action of PTHrP and its receptor in skeletal tissue

- Rabbani S.A., Mitchell J., Roy D.R., Hendy G.N. and Goltzman D. (1988). Influence of the amino-terminus on in vitro biological activity of synthetic parathyroid hormone-like peptides of malignancy. *Endocrinology* 123, 2709-2716.
- Rouleau M.F., Warshawsky H. and Goltzman D. (1986). Parathyroid hormone binding in vivo to renal, hepatic, and skeletal tissues of the rat using a radioautographic approach. *Endocrinology* 118, 919-931.
- Rouleau M.F., Mitchell J. and Goltzman D. (1988). In vivo distribution of parathyroid hormone receptors in bone: evidence that a predominant osseous target cell is not the mature osteoblast. *Endocrinology* 123, 187-191.
- Rouleau M.F., Mitchell J. and Goltzman D. (1990). Characterization of the major parathyroid hormone target cell in the endosteal metaphysis of rat long bones. *J. Bone Miner. Res.* 5, 1043-1053.
- Schipani E., Kruse K. and Jüppner H. (1995). A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. *Science* 268, 98-100.
- Schipani E., Langman C.B., Parfitt A.M., Jensen G.S., Kikuchi S., Kooh S.W., Cole W.G. and Jüppner H. (1996). Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia. *New Engl. J. Med.* 335, 708-714.
- Senior P.V., Heath D.A. and Beck F. (1990). Expression of parathyroid hormone-related protein mRNA in the rat before birth: demonstration by hybridization histochemistry. *J. Mol. Endocrinol.* 6, 281-290.
- Serra R., Karaplis A. and Sohn P. (1999). Parathyroid hormone-related peptide (PTHrP)-dependent and independent effects of transforming growth factor β (TGF β) on endochondral bone formation. *J. Cell Biol.* 145, 783-794.
- Strewler G., Stern J.P.H., Jacob J.W., Eveloff J., Klein R.F., Leung S.C., Rosenblatt M. and Nissenson R.A. (1987). Parathyroid hormonelike protein from human renal carcinoma cells: structural and functional homology with parathyroid hormone. *J. Clin. Invest.* 80, 1803-1807.
- Suda N., Gillespie M.T., Traianedes K., Zhou H., Ho P.W.M., Hards D.K., Allan E.H., Martin T.J. and Moseley J.M. (1996). Expression of parathyroid hormone-related protein in cells of osteoblast lineage. *J. Cell. Physiol.* 166, 94-104.
- Suva L.J., Winslow G.A., Wettenhall R.E.H., Hammond R.G., Moseley J.M., Diefenbach-Jaggard H., Rodda C.P., Kemp B.E., Rodriguez H., Chen E.Y., Hudson P.J., Martin T.J. and Wood W.I. (1987). A parathyroid hormone-related protein implicated malignant hypercalcemia: cloning and expression. *Science* 237, 893-896.
- Thiede M.A. and Rodan G.A. (1988). Expression of a calcium mobilizing parathyroid hormone-like peptide in lactating mammary tissue. *Science* 242, 278-280.
- Thiede M.A., Daifotis A.G., Weir E.C., Brines M.L., Burtis W.J., Ikeda K., Dreyer B.E., Garfield R.E. and Broadus A.E. (1990). Intrauterine occupancy controls expression of the parathyroid hormone-related peptide gene in preterm rat myometrium. *Proc. Natl. Acad. Sci. USA* 87, 6969-6973.
- Thompson D.D., Seedor J.G., Fisher J.E., Rosenblatt M. and Rodan G.A. (1988). Direct action of the parathyroid hormone-like human hypercalcemic factor on bone. *Proc. Natl. Acad. Sci. USA* 85, 5673-5677.
- Tsukazaki T., Ohtsuru A., Enomoto H., Yano H., Motomura K., Ito M., Namba H., Iwasaki K. and Yamashita S. (1995). Expression of parathyroid hormone-related protein in rat articular cartilage. *Calcif. Tissue Int.* 57, 196-200.
- Ureña P., Kong X.F., Abou-Samra A.B., Jüppner H., Kronenberg H.M., Potts Jr J.T. and Segre G.V. (1993). Parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acids are widely distributed in rat tissues. *Endocrinology* 133, 617-623.
- Vortkamp A., Lee K., Lanske B., Segre G.V., Kronenberg H.M. and Tabin C.J. (1996). Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. *Science* 273, 613-623.
- Wasserman R.H. and Fullmer C.S. (1993). Calcium transport proteins, calcium absorption and vitamin D. *Annu. Rev. Physiol.* 45, 375-390.
- Weir E.C., Philbrick W.M., Amling M., Neff L.A., Baron R. and Broadus A. (1996). Targeted overexpression of parathyroid hormone-related peptide in chondrocytes causes chondrodysplasia and delayed endochondral bone formation. *Proc. Natl. Acad. Sci. USA* 93, 10240-10245.

Accepted March 9, 2000